Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients

被引:0
作者
Kim, Chee Jeong [1 ]
机构
[1] Chung Ang Univ, Div Cardiol, Dept Internal Med, Coll Med, Seoul 156756, South Korea
关键词
C-reactive protein; fenofibric acid; HMG CoA reductase inhibitor; lipid; lipoprotein;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with hypertriglyceridemia. Patients with a triglyceride level >= 200 mg/dL were randomly assigned to receive either 200 mg of fenofibrate (n = 54) or general measures (n = 54). A third group of patients with hypercholesterolemia received a statin (n = 54). Patients with a CRP level 10 mg/L were excluded. CRP levels were measured before and after 2 months of therapy. Fenofibrate did not reduce CRP levels (1.74 +/- 1.74 vs. 1.54 +/- 1.66 mg/L, P = 0.27) nor did general measures (P = 0.85). Statin reduced CRP levels (P = 0.002). In patients with baseline CRP levels of 3 mg/dL, CRP levels were decreased in both the fenofibrate and control groups (P = 0.026 and 0.008, respectively). Changes in CRP levels were associated only with baseline CRP levels in both groups (P = 0.001 and 0.049, respectively). When all hypertriglyceridemic patients were divided into 2 subgroups according to changes in body weights, CRP levels decreased in patients who reduced their body weight >= I kg (n = 29, P 0.030), and were not changed in the other patients (n 79, P = 0.67). In summary, fenofibrate failed to decrease CRP levels in patients with hypertriglyceridemia. An antiinflammatory mechanism may not play a significant role in the cardioprotective effect of fenofibrate.
引用
收藏
页码:758 / 763
页数:6
相关论文
共 25 条
[1]   Role of C-reactive protein in cardiovascular disease [J].
Backes, JM ;
Howard, PA ;
Moriarty, PM .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (01) :110-118
[2]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[3]  
Cortellaro M, 2000, THROMB HAEMOSTASIS, V83, P549
[4]   Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome [J].
Després, JP ;
Lemieux, I ;
Pascot, A ;
Alméras, N ;
Dumont, M ;
Nadeau, A ;
Bergeron, J ;
Prud'homme, D .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (04) :702-703
[5]   Body mass index, diabetes, and C-reactive protein among US adults [J].
Ford, ES .
DIABETES CARE, 1999, 22 (12) :1971-1977
[6]   Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia [J].
Gómez-Gerique, JA ;
Ros, E ;
Oliván, J ;
Mostaza, JM ;
Vilardell, M ;
Pintó, X ;
Civeira, F ;
Hernández, A ;
da Silva, PM ;
Rodriguez-Botaro, A ;
Zambón, D ;
Lima, J ;
Díaz, C ;
Aristegui, R ;
Sol, JM ;
Chaves, J ;
Hernández, G .
ATHEROSCLEROSIS, 2002, 162 (02) :245-251
[7]   Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women [J].
Hak, AE ;
Stehouwer, CDA ;
Bots, ML ;
Polderman, KH ;
Schalkwijk, CG ;
Westendorp, ICD ;
Hofman, A ;
Witteman, JCM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (08) :1986-1991
[8]   Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women [J].
Heilbronn, LK ;
Noakes, M ;
Clifton, PM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (06) :968-970
[9]  
Jialal I, 2001, CIRCULATION, V103, P1933
[10]   Role of C-reactive protein in the assessment of cardiovascular risk [J].
Jialal, I ;
Devaraj, S .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (02) :200-+